{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:47:00Z","timestamp":1790880420212,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":329,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.lrr.2024.100491","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:11:56Z","timestamp":1732666316000},"page":"100491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report"],"prefix":"10.1016","volume":"22","author":[{"given":"E.","family":"Amabile","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Martelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MT.","family":"Petrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.lrr.2024.100491_bib0001","first-page":"1042","article-title":"Poems syndrome: a rare and relatively unknown disease","volume":"2","author":"Finsinger","year":"2015","journal-title":"Ann. Hematol. Oncol."},{"key":"10.1016\/j.lrr.2024.100491_bib0002","first-page":"61","article-title":"The unclear role of VEGF in POEMS syndrome: therapeutic implications of neoangiogenesis in a rare plasma cell disorder","volume":"7","author":"Lapietra","year":"2021","journal-title":"J. Cancer Metastasis Treat."},{"issue":"12","key":"10.1016\/j.lrr.2024.100491_bib0003","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1002\/ajh.27081","article-title":"POEMS syndrome: Update on diagnosis, risk-stratification, and management","volume":"98","author":"Dispenzieri","year":"2023","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.lrr.2024.100491_bib0004","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clml.2021.10.007","article-title":"POEMS Syndrome: real world experience in diagnosis and systemic therapy - 108 patients multicenter analysis","volume":"22","author":"Jurczyszyn","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.lrr.2024.100491_bib0005","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/j.clml.2021.07.033","article-title":"Efficacy and safety of regimens used for the treatment of POEMS syndrome- a systematic review","volume":"22","author":"Faizan","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"1","key":"10.1016\/j.lrr.2024.100491_bib0006","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1186\/s13256-022-03552-y","article-title":"Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report","volume":"16","author":"Taenaka","year":"2022","journal-title":"J. Med. Case Rep."},{"issue":"3","key":"10.1016\/j.lrr.2024.100491_bib0007","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1097\/HS9.0000000000000381","article-title":"Upfront Daratumumab with Lenalidomide and dexamethasone for POEMS syndrome","volume":"4","author":"Gavriatopoulou","year":"2020","journal-title":"Hemasphere"},{"issue":"11","key":"10.1016\/j.lrr.2024.100491_bib0008","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol."},{"issue":"10218","key":"10.1016\/j.lrr.2024.100491_bib0009","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.lrr.2024.100491_bib0010","unstructured":"Treatment of POEMS syndrome with Daratumumab https:\/\/clinicaltrials.gov\/study\/NCT04396496."}],"updated-by":[{"DOI":"10.1016\/j.lrr.2025.100499","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000}}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048924000815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048924000815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T20:38:01Z","timestamp":1733431081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048924000815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":10,"alternative-id":["S2213048924000815"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2024.100491","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.lrr.2025.100499","asserted-by":"object"}]},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line therapy with daratumumab, lenalidomide and dexamethasone for patient with POEMS syndrome: A case report","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2024.100491","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100491"}}